Further, we identified that two ceRNAs networks, LINC00589-miR-100-DLG5 axis and LINC00589-miR-452-PRDM16 axis, that mediate multiple suppressor roles of LINC00589. Our findings suggest that these LINC00589 ceRNA networks could be valuable for predicting trastuzumab efficacy and prognosis, as well as providing promising therapeutic targets for HER2-positive breast cancer in future translational applications. This evidence concerns the gene ERBB2 and breast cancer.